#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

“But ultimately, of course, once insulin could be synthetically produced, you could create a therapy to save the life of somebody with type 1 diabetes. More recently, of course, people will be- very familiar with the GLP-1s. We're going to talk about that because in the GLP-1 world, we're not typically giving people the exact same peptide, but we'll come back to that.”

“We're going to actually talk about these a little differently. So we're definitely not going to talk about insulin today. We will talk a little bit about GLP-1, but from a sort of regulatory standpoint. In medical terms, I would say a peptide broadly refers to an FDA-approved therapeutic molecule, again, like insulin or GLP-1 drugs.”

“we'll point to GLP-1 agonists, insulin, and even longer proteins that are probably on the verge of still being peptides like HCG that are clearly clinically efficacious. So I think what we want”

“and then we're going to run our framework through a handful of examples in detail. SS-31, talk about the background, the biology, and the types of conditions it has been studied for.”

“we've come up with our own point of view on. Okay. So what are the ones we're going to start on? We're going to kind of go a little deep into the following. SS31, melanitin to CJC1295 and BPC157.”

“and talk about how these things are subject to some regulatory oversight, et cetera. Let's just dive into it. Let's do it. Let's start with the first one, SS31. Let's start with the question, is there a viable mechanism of action that we know for it? Thank you for listening to today's sneak peek AMA episode of The Drive.”

“no discussion on the topic would be complete without that, the origin story, the proposed mechanisms, and the nature of the animal and human evidence that's often cited. We're going to talk about the role of patents and the incentives in drug development, and why some compounds do or don't advance through formal clinical pipelines.”

“melanitan 2, CJC 1295, and BPC 157. Why did we pick those four? They're incredibly popular. They're probably the ones I get asked about the most from patients, friends, anybody.”

“We're going to kind of go a little deep into the following: SS31, melanitan 2, CJC 1295, and BPC 157. Why did we pick those four? They're incredibly popular. They're probably the ones I get asked about the most from patients, friends, anybody.”

“Now, there are some interesting examples. So Tylenol is an exception. Believe it or not, we don't actually know how Tylenol works. We don't know how lithium works. You know, we did a newsletter on this somewhat recently talking about lithium for potential cognitive benefits. We don't actually know how it works. There's some speculation, but we don't know.”

“Something like Mucinex, we don't really know how that works.”

“Now, there are some interesting examples. So Tylenol is an exception. Believe it or not, we don't actually know how Tylenol works. We don't know how lithium works. You know, we did a newsletter on this somewhat recently talking about lithium for potential cognitive benefits.”